Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Radioimaging on the ASK


Overview


Positron emission tomography can be used to visualize antibodies and other biologics non-invasively, in vivo. PerkinElmer offers radionuclides for labeling biologics for use in in vivo imaging research. Two positron emitters, Zr-89 and I-124, are offered for molecular imaging using immuno-positron emission tomography (immuno-PET) or Cerenkov luminescence imaging (CLI) techniques. Both Zr-89 and I-124 are long-living positron emitters, providing an advantage over other emitters such as 18F and 86Y when labeling large biomolecules (including therapeutic monoclonal antibodies) that accumulate more-slowly in vivo. Immuno-PET with Zr-89 and I-124 radionuclides enables noninvasive imaging of whole, intact antibodies.


 89Zr124I
Half-Life78.4 hrs (3.26 days)100.3 hrs (4.18 days)
EnergyBeta (0.389 MeV)Beta (1.54 MeV; 2.14 MeV)
Primary applicationLabeling internalizing antibodies (mAbs)Labeling non-internalizing mAbs
LabelingA chelator (DFO) is most commonly used to label antibodies with Zr-89General iodination techniques can be used for direct labeling; Iodogen® method is recommended


Products and catalog numbers


 Zr-89I-124
Catalog #NEZ308000MCNEZ309000MC
Vial2 mL Wheaton NextGen V-Vial2 mL Wheaton NextGen V-Vial
VolumeFixedFixed
Minimum Order1 mCi (1 mCi increments)1 mCi (1 mCi increments)
GMPYesYes
CalibrationFixed-MondayFixed-Thursday
Shipping/Storage ConditionsAmbientAmbient

For immuno-PET research applications, Zr-89 is commonly used for internalizing monoclonal antibodies because it is trapped inside the cell after internalization of the antibody (residualization). I-124 is commonly used for labeling non-internalizing antibodies, as it is non-residualizing. The target antibody is labeled with I-124 using direct labeling methods. Both 124I and 89Zr have a relatively long half-life (beyond that of 18F, Gallium-68, 64Cu, or 86Y), enabling imaging at later timepoints needed for larger research biologics.


Labeling antibodies with Zr-89


Antibodies are typically labeled indirectly with Zr-89 using a chelator, though direct labeling approaches have been described for labeling other biomolecules with Zr-89. The most common method for labeling is using Desferrioxamine B  (DFO). DFO is available as a salt, or in reactive forms such as isothiocyanate (ITC; labels lysine residues), maleimide (labels thiol groups/cysteine residues), and tetrafluorophenolic ester/Fe3+ derivatives (labels lysine residues). 


Labeling antibodies with I-124


Antibodies are typically labeled directly via radioiodination of tyrosine residues with electropositive radioiodine. Chloramine T and Iodogen® methods can be used for oxidation of the 124I radioiodide, for direct antibody labeling.


FAQs


Products are for research use only. Not for use in diagnostic procedures.

Q. Which PET isotope is the most suitable for my application?
A. This depends on the antibody you want to image. If it’s an internalizing antibody, then use residualizing Zr-89.

Q. Is Desferal (Df) the only suitable chelator for stable incorporation of Zr-89?
A. Yes, DOTA, NOTA or DTPA are not suitable for stable incorporation of Zr-89.

Q. Which Df chelator is best option for my research?
A. This depends on the type of research. The TFP-nSuc-Df chelator is used in clinical trials safely for many years and is commercially available at ABX (www.ABX.com), but requires the extra Fe-removal step at pH 4. The Df-Bz-NCS chelator was recently introduced in the clinic and is commercially available at Macrocyclics. Both of these are suitable for use in research applications.

Q. What are the minimum quantities of mAb to obtain reliable labelling yields?
A.

  • Zr-89: we prefer to start the conjugation of the Df-chelator to the antibody with at least 2 mg mAb, and then subsequently radiolabel at least 0.5 mg mAb-Df.
  • I-124: with the Iodogen method it is possible to radiolabel small amounts of mAb (starting with 50 µg) up to 5 mg.


References


  1. Fischer, G., Seibold, U., Schirrmacher, R., Wängler, B. & Wängler, C. (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules18, 6469–6490 (2013). Link
  2. Treglia, G. & Salsano, M. PET imaging using radiolabelled antibodies: future direction in tumor diagnosis and correlate applications. Research and Reports in Nuclear Medicine 9 (2013).
  3. Verel, I. et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm.18, 655–661 (2003). Link
  4. Wu, A. M. & Olafsen, T. Antibodies for molecular imaging of cancer. Cancer J14, 191–197 (2008). Link
  5. Koehler, L., Gagnon, K., McQuarrie, S. & Wuest, F. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules15, 2686–2718 (2010). Link


Products are for research use only. Not for use in diagnostic procedures.